Workflow
Evommune(EVMN)
icon
Search documents
Evommune Announces Commencement of Initial Public Offering
Prnewswire· 2025-10-30 10:30
Core Points - Evommune, Inc. has filed a registration statement for an initial public offering (IPO) of its common stock, offering 9,375,000 shares at an expected price between $15.00 and $17.00 per share [1] - The company plans to grant underwriters a 30-day option to purchase an additional 1,406,250 shares in connection with the IPO [1] - Evommune's common stock is expected to be listed on the New York Stock Exchange under the symbol "EVMN" [1] - The registration statement is anticipated to become effective on November 5, 2025, allowing the company to price the offering shortly thereafter [1] - Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor are acting as joint book-running managers for the proposed offering [2] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies targeting chronic inflammatory diseases [5] - The company's mission is to enhance patients' daily lives and mitigate long-term effects of uncontrolled inflammation caused by existing therapy limitations [5] - Evommune is advancing a portfolio of differentiated product candidates aimed at addressing key drivers of chronic inflammation [5]
慢性炎症性疾病生物科技公司Evommune(EVMN.US)IPO定价15-17美元/股 拟筹资1.5亿美元
Zhi Tong Cai Jing· 2025-10-20 08:04
Group 1 - Evommune, a biotech company focused on therapies for chronic inflammatory diseases, announced its IPO terms, aiming to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 [1] - The company's lead candidate, EVO756, is a potent and selective MRGPRX2 oral small molecule antagonist for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), currently in a Phase 2b trial with results expected in the second half of 2026 [1] - Evommune's second candidate, EV0301, is a long-acting fusion protein for treating atopic dermatitis (AD) and ulcerative colitis (UC), with plans to initiate a Phase 2 trial for moderate to severe UC patients in 2026 [1] Group 2 - Founded in 2020, Evommune reported revenue of $3 million for the 12 months ending June 30, 2025, and plans to list on the New York Stock Exchange under the ticker "EVMN" [2] - The company has appointed Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald as joint book-running managers for the IPO, with the final pricing expected during the week of November 3, 2025 [2]
Evommune Aims For IPO In Bifurcated Biopharma Market
Seeking Alpha· 2025-10-14 20:01
He also leads the investing group IPO Edge , which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initi ...
美国 IPO 市场本周动态:多领域企业密集上市,SPAC与微型股成亮点
美股研究社· 2025-10-11 09:31
Core Insights - The U.S. IPO market remains active despite government shutdown, with 6 traditional IPOs and 2 SPACs launched this week, alongside 13 companies filing for initial public offerings [1][12]. Group 1: IPO Activity - Alliance Laundry Holdings (ALH) raised $826 million, pricing at the upper limit of its range, achieving a market cap of $4.5 billion, and saw a 14% stock price increase [1]. - Phoenix Education Partners (PXED) raised $136 million, pricing at the midpoint of its range, with a market cap of $1.3 billion and a 13% stock price increase [1]. - Ping An Good Doctor (POM) raised $20 million, pricing at the lower limit of its range, with a market cap of $474 million and a 9% stock price increase [2]. - One and One Green Tech (YDDL) raised $10 million, pricing at the midpoint of its range, achieving a market cap of $27 million and a significant 31% stock price increase [2]. - Leifras (LFS) raised $5 million, pricing at the lower limit of its range, with a market cap of $10.5 million, but experienced a 5% stock price decline [2]. - Turn Therapeutics (TTRX) debuted via direct listing at $10, but saw a 26% decline in stock price [3]. Group 2: SPAC Activity - Two SPACs completed their listings: GigCapital8 (GIWWU) raised $220 million and Lake Superior Acquisition (LKSPU) raised $100 million, focusing on energy, social media, and consumer goods [4]. - Five SPACs filed for IPOs, including Xsolla SPAC 1 (XSOLU.RC) and Alussa Energy Acquisition II (ALUBU), both aiming to raise $250 million [8][10]. Group 3: Upcoming IPOs and Market Trends - 13 companies filed for IPOs, including BillionToOne (BLLN), Evommune (EVMN), and Central Bancompany (CBC), each planning to raise $100 million [6]. - The SEC issued new guidelines allowing companies to announce pricing ranges and set final pricing above the range, which may encourage more companies to proceed with listings amid the government shutdown [12].